PCM
GALT icon

Peak Capital Management’s Galectin Therapeutics GALT Stock Holding History

Peak Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,000
Closed -$38K – 100
2018
Q2 		$38K Buy
+6,000
New +$29.2K 0.02% 92

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Peak Capital Management's GALT Position: Q3 2018 in Review

Peak Capital Management sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 6,000 shares — an estimated $38K sold.

Peak Capital Management first reported a position in GALT in Q2 2018 and held it in 1 quarter. The position peaked at $38K in Q2 2018. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

  • Peak Capital Management reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Peak Capital Management sold 6,000 Galectin Therapeutics shares in Q3 2018, an estimated $38K.
  • Peak Capital Management first reported a position in Galectin Therapeutics in Q2 2018 and held it in 1 quarter.
  • Peak Capital Management's Galectin Therapeutics position peaked at $38K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on Peak Capital Management's 13F filing for Q3 2018, filed 20 Nov 2018.